Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study

Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical care (London, England) England), 2013-08, Vol.17 (4), p.R174-R174, Article R174
Hauptverfasser: Rocco, Monica, Montini, Luca, Alessandri, Elisa, Venditti, Mario, Laderchi, Amalia, De Pascale, Gennaro, Raponi, Giammarco, Vitale, Michela, Pietropaoli, Paolo, Antonelli, Massimo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page R174
container_issue 4
container_start_page R174
container_title Critical care (London, England)
container_volume 17
creator Rocco, Monica
Montini, Luca
Alessandri, Elisa
Venditti, Mario
Laderchi, Amalia
De Pascale, Gennaro
Raponi, Giammarco
Vitale, Michela
Pietropaoli, Paolo
Antonelli, Massimo
description Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics. The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome. The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone. In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.
doi_str_mv 10.1186/cc12853
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4056524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534778253</galeid><sourcerecordid>A534778253</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-d2ec76e5bdbe23440541537d12ebd04f77415586253502dbe066c503e36e5bb13</originalsourceid><addsrcrecordid>eNptUl1r3TAMDWNj7bqxfzAMe9hT2jj-SO4eBqXsCwqDscHegmMrN2oTO9jOpfff7adNl9uVFYYfZElH50hCRfGaV-ect_rCWl63SjwpTrnUutTV5tdT-gstSwqrk-JFSjdVxZtWi-fFSS02UvFNc1r8_o7plg3G5hATG0Jkxq4Z2C06D3uG_maNB8NsxIzWTBN508QWkxF8TiyCBdyh37IRtyMhczQ78GFNzIUEiYWB2TBhykQyQx6Nh7ROQ_CGZIx3F6QZ8giReVjGGHK4Q0uJjD0GkkzvmSGVHENawGbcAfGNIWaW8ur2L4tng5kSvLq3Z8XPTx9_XH0pr799_np1eV1aKXQuXQ220aB610MtpKyU5Eo0jtfQu0oOTUO-anVN26pqAlVaW1UJEIeinouz4sORd1n7GZyFw6BTt0ScTdx3wWD3OONx7LZh15GUVrUkgrdHgq2ZoEM_BILZGZPtLpWQTdOSNqHO_4Oi52BGGzwMSPFHBe-OBZYWlCIMDy3xqjvcRnd_G4R88-8ED7i_xyD-ABaDumE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>SpringerLink Journals - AutoHoldings</source><source>Springer Nature OA Free Journals</source><creator>Rocco, Monica ; Montini, Luca ; Alessandri, Elisa ; Venditti, Mario ; Laderchi, Amalia ; De Pascale, Gennaro ; Raponi, Giammarco ; Vitale, Michela ; Pietropaoli, Paolo ; Antonelli, Massimo</creator><creatorcontrib>Rocco, Monica ; Montini, Luca ; Alessandri, Elisa ; Venditti, Mario ; Laderchi, Amalia ; De Pascale, Gennaro ; Raponi, Giammarco ; Vitale, Michela ; Pietropaoli, Paolo ; Antonelli, Massimo</creatorcontrib><description>Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics. The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome. The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone. In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.</description><identifier>ISSN: 1364-8535</identifier><identifier>EISSN: 1466-609X</identifier><identifier>EISSN: 1364-8535</identifier><identifier>DOI: 10.1186/cc12853</identifier><identifier>PMID: 23945197</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acute Kidney Injury - chemically induced ; Acute Kidney Injury - diagnosis ; Acute Kidney Injury - epidemiology ; Acute renal failure ; Adult ; Aged ; Aminoglycosides ; Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - adverse effects ; Chronic kidney failure ; Cohort Studies ; Colistin ; Colistin - administration &amp; dosage ; Colistin - adverse effects ; Critical Illness - epidemiology ; Critical Illness - therapy ; Critically ill ; Diabetes ; Drug resistance in microorganisms ; Evidence (Law) ; Female ; Health aspects ; Hospital patients ; Humans ; Infusions, Intravenous ; Kidney - drug effects ; Kidney - pathology ; Male ; Medical research ; Medicine, Experimental ; Middle Aged ; Physiological aspects ; Prospective Studies ; Retrospective Studies ; Risk Factors ; Sepsis - drug therapy ; Sepsis - epidemiology ; Septic shock</subject><ispartof>Critical care (London, England), 2013-08, Vol.17 (4), p.R174-R174, Article R174</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>Copyright © 2013 Rocco et al.; licensee BioMed Central Ltd. 2013 Rocco et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-d2ec76e5bdbe23440541537d12ebd04f77415586253502dbe066c503e36e5bb13</citedby><cites>FETCH-LOGICAL-c436t-d2ec76e5bdbe23440541537d12ebd04f77415586253502dbe066c503e36e5bb13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056524/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056524/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23945197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rocco, Monica</creatorcontrib><creatorcontrib>Montini, Luca</creatorcontrib><creatorcontrib>Alessandri, Elisa</creatorcontrib><creatorcontrib>Venditti, Mario</creatorcontrib><creatorcontrib>Laderchi, Amalia</creatorcontrib><creatorcontrib>De Pascale, Gennaro</creatorcontrib><creatorcontrib>Raponi, Giammarco</creatorcontrib><creatorcontrib>Vitale, Michela</creatorcontrib><creatorcontrib>Pietropaoli, Paolo</creatorcontrib><creatorcontrib>Antonelli, Massimo</creatorcontrib><title>Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study</title><title>Critical care (London, England)</title><addtitle>Crit Care</addtitle><description>Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics. The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome. The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone. In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.</description><subject>Acute Kidney Injury - chemically induced</subject><subject>Acute Kidney Injury - diagnosis</subject><subject>Acute Kidney Injury - epidemiology</subject><subject>Acute renal failure</subject><subject>Adult</subject><subject>Aged</subject><subject>Aminoglycosides</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Chronic kidney failure</subject><subject>Cohort Studies</subject><subject>Colistin</subject><subject>Colistin - administration &amp; dosage</subject><subject>Colistin - adverse effects</subject><subject>Critical Illness - epidemiology</subject><subject>Critical Illness - therapy</subject><subject>Critically ill</subject><subject>Diabetes</subject><subject>Drug resistance in microorganisms</subject><subject>Evidence (Law)</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hospital patients</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Physiological aspects</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Sepsis - drug therapy</subject><subject>Sepsis - epidemiology</subject><subject>Septic shock</subject><issn>1364-8535</issn><issn>1466-609X</issn><issn>1364-8535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUl1r3TAMDWNj7bqxfzAMe9hT2jj-SO4eBqXsCwqDscHegmMrN2oTO9jOpfff7adNl9uVFYYfZElH50hCRfGaV-ect_rCWl63SjwpTrnUutTV5tdT-gstSwqrk-JFSjdVxZtWi-fFSS02UvFNc1r8_o7plg3G5hATG0Jkxq4Z2C06D3uG_maNB8NsxIzWTBN508QWkxF8TiyCBdyh37IRtyMhczQ78GFNzIUEiYWB2TBhykQyQx6Nh7ROQ_CGZIx3F6QZ8giReVjGGHK4Q0uJjD0GkkzvmSGVHENawGbcAfGNIWaW8ur2L4tng5kSvLq3Z8XPTx9_XH0pr799_np1eV1aKXQuXQ220aB610MtpKyU5Eo0jtfQu0oOTUO-anVN26pqAlVaW1UJEIeinouz4sORd1n7GZyFw6BTt0ScTdx3wWD3OONx7LZh15GUVrUkgrdHgq2ZoEM_BILZGZPtLpWQTdOSNqHO_4Oi52BGGzwMSPFHBe-OBZYWlCIMDy3xqjvcRnd_G4R88-8ED7i_xyD-ABaDumE</recordid><startdate>20130814</startdate><enddate>20130814</enddate><creator>Rocco, Monica</creator><creator>Montini, Luca</creator><creator>Alessandri, Elisa</creator><creator>Venditti, Mario</creator><creator>Laderchi, Amalia</creator><creator>De Pascale, Gennaro</creator><creator>Raponi, Giammarco</creator><creator>Vitale, Michela</creator><creator>Pietropaoli, Paolo</creator><creator>Antonelli, Massimo</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20130814</creationdate><title>Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study</title><author>Rocco, Monica ; Montini, Luca ; Alessandri, Elisa ; Venditti, Mario ; Laderchi, Amalia ; De Pascale, Gennaro ; Raponi, Giammarco ; Vitale, Michela ; Pietropaoli, Paolo ; Antonelli, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-d2ec76e5bdbe23440541537d12ebd04f77415586253502dbe066c503e36e5bb13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acute Kidney Injury - chemically induced</topic><topic>Acute Kidney Injury - diagnosis</topic><topic>Acute Kidney Injury - epidemiology</topic><topic>Acute renal failure</topic><topic>Adult</topic><topic>Aged</topic><topic>Aminoglycosides</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Chronic kidney failure</topic><topic>Cohort Studies</topic><topic>Colistin</topic><topic>Colistin - administration &amp; dosage</topic><topic>Colistin - adverse effects</topic><topic>Critical Illness - epidemiology</topic><topic>Critical Illness - therapy</topic><topic>Critically ill</topic><topic>Diabetes</topic><topic>Drug resistance in microorganisms</topic><topic>Evidence (Law)</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hospital patients</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Physiological aspects</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Sepsis - drug therapy</topic><topic>Sepsis - epidemiology</topic><topic>Septic shock</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rocco, Monica</creatorcontrib><creatorcontrib>Montini, Luca</creatorcontrib><creatorcontrib>Alessandri, Elisa</creatorcontrib><creatorcontrib>Venditti, Mario</creatorcontrib><creatorcontrib>Laderchi, Amalia</creatorcontrib><creatorcontrib>De Pascale, Gennaro</creatorcontrib><creatorcontrib>Raponi, Giammarco</creatorcontrib><creatorcontrib>Vitale, Michela</creatorcontrib><creatorcontrib>Pietropaoli, Paolo</creatorcontrib><creatorcontrib>Antonelli, Massimo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Critical care (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rocco, Monica</au><au>Montini, Luca</au><au>Alessandri, Elisa</au><au>Venditti, Mario</au><au>Laderchi, Amalia</au><au>De Pascale, Gennaro</au><au>Raponi, Giammarco</au><au>Vitale, Michela</au><au>Pietropaoli, Paolo</au><au>Antonelli, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study</atitle><jtitle>Critical care (London, England)</jtitle><addtitle>Crit Care</addtitle><date>2013-08-14</date><risdate>2013</risdate><volume>17</volume><issue>4</issue><spage>R174</spage><epage>R174</epage><pages>R174-R174</pages><artnum>R174</artnum><issn>1364-8535</issn><eissn>1466-609X</eissn><eissn>1364-8535</eissn><abstract>Use of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics. The cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome. The 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone. In severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23945197</pmid><doi>10.1186/cc12853</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1364-8535
ispartof Critical care (London, England), 2013-08, Vol.17 (4), p.R174-R174, Article R174
issn 1364-8535
1466-609X
1364-8535
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4056524
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; SpringerLink Journals - AutoHoldings; Springer Nature OA Free Journals
subjects Acute Kidney Injury - chemically induced
Acute Kidney Injury - diagnosis
Acute Kidney Injury - epidemiology
Acute renal failure
Adult
Aged
Aminoglycosides
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - adverse effects
Chronic kidney failure
Cohort Studies
Colistin
Colistin - administration & dosage
Colistin - adverse effects
Critical Illness - epidemiology
Critical Illness - therapy
Critically ill
Diabetes
Drug resistance in microorganisms
Evidence (Law)
Female
Health aspects
Hospital patients
Humans
Infusions, Intravenous
Kidney - drug effects
Kidney - pathology
Male
Medical research
Medicine, Experimental
Middle Aged
Physiological aspects
Prospective Studies
Retrospective Studies
Risk Factors
Sepsis - drug therapy
Sepsis - epidemiology
Septic shock
title Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A08%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20for%20acute%20kidney%20injury%20in%20critically%20ill%20patients%20receiving%20high%20intravenous%20doses%20of%20colistin%20methanesulfonate%20and/or%20other%20nephrotoxic%20antibiotics:%20a%20retrospective%20cohort%20study&rft.jtitle=Critical%20care%20(London,%20England)&rft.au=Rocco,%20Monica&rft.date=2013-08-14&rft.volume=17&rft.issue=4&rft.spage=R174&rft.epage=R174&rft.pages=R174-R174&rft.artnum=R174&rft.issn=1364-8535&rft.eissn=1466-609X&rft_id=info:doi/10.1186/cc12853&rft_dat=%3Cgale_pubme%3EA534778253%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23945197&rft_galeid=A534778253&rfr_iscdi=true